Before founding Sound Bioventures, Mr. Breum was a Senior Partner at Lundbeckfonden Ventures, where he worked for 12 years, and led investments and served as a member of the board of directors in companies including: Sanifit (sold to Vifor Pharma), Aura Biosciences (Nasdaq: AURA), Spero Therapeutics (Nasdaq: SPRO), Nexstim (Nasdaq First North: NXTM), Biomup (Euronext: BUP).

Prior to that, he was CEO of the venture backed diagnostics company, ilochip A/S (technology sold to DELTA, now FORCE Technology). Before that Mr Breum worked in the pharmaceutical industry for 15 years in a range of different positions in R&D, Project Management, Sourcing, Quality Assurance, and Business Development & Strategy, for Lundbeck, Novo Nordisk and Niels Clauson-Kaas. While working at Lundbeck, Mr. Breum was part of spinning Veloxis (sold to Asahi Kasei) out of Lundbeck, and served on the board of the Lundbeck Foundation.

Mr. Breum holds a MSc in organic chemistry and an Executive MBA, both from the Technical University of Denmark.